Biopharmaceutical drug-development company focused on therapeutic products for diabetes, obesity, and other metabolic diseases
Biopharmaceutical drug-development company focused on therapeutic products for diabetes, obesity, and other metabolic diseases. Its pipeline included peptide-based drug candidates, including a glucagon analog for emergency treatment of hypoglycemia. The company used proprietary peptide chemistry and licensed drug candidates from Indiana University Research and Technology Corporation; it was acquired by Roche in 2010.